Clinical Trials Sponsored by Novo Nordisk A/S

Total 1551 results

Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men

Non-alcoholic Steatohepatitis

Japan
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (CONCLUDE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Canada, Denmark, Hungary, Serbia, Germany, Greece, Romania, Estonia, Norway
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

Obesity | Overweight | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors (explorer™5)

Haemophilia A | Haemostasis

United Kingdom, France, United States, Sweden, Spain, Turkey, Japan, Italy, Germany, Thailand, Ukraine
Novo Nordisk A/S

Completed

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Non-alcoholic Steatohepatitis | Hepatobiliary Disorders

United States, Russian Federation, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Spain, France, Bulgaria, Canada, Australia, Greece, Japan, Finland, Puerto Rico
Novo Nordisk A/S

Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

Diabetes Mellitus, Type 2

Sweden, Denmark
Novo Nordisk A/S

Completed

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (STEP 3)

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (STEP 2)

Obesity | Overweight

United States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea

Diabetes Mellitus, Type 2

Korea, Republic of
Novo Nordisk A/S

Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (SURE SPAIN)

Diabetes Mellitus, Type 2

Spain
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia

Diabetes Mellitus, Type 2

Russian Federation
Novo Nordisk A/S

Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Diabetes Mellitus, Type 2

Switzerland
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Overweight or Obesity | Metabolism and Nutrition Disorders

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, Austria, Japan, Norway, Puerto Rico
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia (UPDATES)

Diabetes Mellitus, Type 2

Saudi Arabia
Novo Nordisk A/S

Completed

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (PIONEER 10)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Terminated

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

United States, Germany, United Kingdom
Novo Nordisk A/S

Completed

Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern

Severe Postpartum Haemorrhage

Switzerland
Novo Nordisk A/S

Completed

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, United Kingdom, Canada, Spain, Denmark, Austria, Serbia, South Africa, Sweden, Italy, Bulgaria, Germany, Malaysia
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

France, Israel, Austria, Spain, Switzerland, North Macedonia, Norway, Slovenia, Belgium, Sweden
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Healthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States, Poland, India, Japan, Russian Federation, United Kingdom, Germany, Sweden, Israel, Malaysia, Turkey, South Africa, Australia, Latvia, Lithuania, Romania, Brazil, Norway, Ukraine
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia
Novo Nordisk A/S

Completed

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Noonan Syndrome | Genetic Disorder

Japan
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Withdrawn

A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria (B Simple)

Diabetes Mellitus, Type 2

Algeria
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (DUAL™ II China)

Diabetes Mellitus, Type 2 | Diabetes

Hong Kong, China
Novo Nordisk A/S

Completed

A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

Healthy

China
Novo Nordisk A/S

Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (alleviate 1)

Congenital Bleeding Disorder | Haemophilia A

United States, Austria, Serbia, Germany, Japan, France
Novo Nordisk A/S

Completed

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

Obesity | Overweight | Healthy Volunteers

United States
Novo Nordisk A/S

Completed

RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan (RESILIENT)

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia (eTHINK)

Haemophilia A | Haemophilia B

United States
Novo Nordisk A/S

Completed

An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Mellitus, Type 1

Israel, United Kingdom, France, Netherlands, Spain, Finland, Malaysia, Norway, Italy, Germany, Poland, Romania, Portugal, Ireland, Croatia, Greece
Novo Nordisk A/S

Completed

French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin

Growth Hormone Disorder | Adult Growth Hormone Deficiency

France
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (SUSTAIN 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, Spain, United Kingdom, Finland, Ireland, Germany, Greece, Puerto Rico, Romania, Bulgaria, Latvia, Hong Kong, Lithuania, Portugal
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (SUSTAIN 10)

Diabetes Mellitus, Type 2 | Diabetes

Italy, Spain, United Kingdom, France, Sweden, Finland, Poland, Slovenia, Hungary, Germany, Bulgaria, Czechia
Novo Nordisk A/S

Completed

Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy

Growth Hormone Deficiency in Children

Germany
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Obesity and Overweight

United States
Novo Nordisk A/S

Completed

A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

Diabetes Mellitus, Type 2 | Diabetes

India, Italy, Spain, Austria, Finland, Hungary, Turkey, France, United Kingdom, Switzerland, Bulgaria, Germany, South Africa, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Israel, Italy, Mexico, Puerto Rico, Russian Federation, Spain, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Taiwan, Finland, Norway, Serbia, South Africa, Turkey, Canada, France, Germany, Korea, Republic of and more
Novo Nordisk A/S

Completed

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Obesity | Overweight

United States

3

Subscribe